Mission Therapeutics Doses First Patient in Parkinson's Study of Potential Disease-Modifying Treatment
News related to:Mission Therapeutics · 2 min read
CAMBRIDGE, United Kingdom, Oct. 15, 2026 /CourierPR/ -- Mission Therapeutics has taken a significant step in its quest to develop a potential disease-modifying treatment for Parkinson's disease with the dosing of the first patient in its Phase 1b study of MTX325. The company, a clinical-stage biotechnology firm, is exploring the drug's ability to improve mitochondrial control and potentially alter the course of the neurodegenerative condition.
MTX325 is a first-in-class, highly potent, orally bioavailable, and brain-penetrant USP30 inhibitor. The Phase 1b study, known as MTX325-101, is being conducted in the UK, Europe, and Australia. It aims to assess the drug's clinical proof-of-mechanism, safety, and tolerability in 36 patients with mild to moderate Parkinson's disease. The study is part of Mission Therapeutics' broader efforts to understand how MTX325 can impact the disease, following the successful completion of a Phase 1a study in healthy volunteers.
Dr. Sarah Fritchley, Chief Development Officer of Mission Therapeutics, emphasized the significance of this milestone.
The drug's mechanism of action is designed to enhance the clearance of dysfunctional mitochondria, support cell health, and reduce inflammation. Preclinical studies have shown that MTX325 can increase mitophagy, reduce alpha-synuclein accumulation, and provide beneficial effects on nigrostriatal dopaminergic neurons. A Phase 1a study in healthy volunteers demonstrated high central nervous system penetration, and a PET study confirmed the drug's distribution into brain parenchyma.
The Phase 1b study is structured to establish clinical proof-of-mechanism and assess biological and pathophysiological responses using a wide range of biomarkers and imaging measures. Recruitment is ongoing, with 36 participants expected to enroll across the UK, Europe, and Australia. A data readout is anticipated in late 2027.
Mission Therapeutics is backed by a roster of blue-chip investors, including Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital. The company holds composition of matter IP exclusivity for MTX325 through 2041, ensuring a long-term focus on the development of this potential therapeutic.
The company's efforts are part of a broader strategy to restore cellular health and function by promoting the removal of dysfunctional mitochondria. This approach could have far-reaching implications for the treatment of Parkinson's disease and other neurodegenerative conditions.